Intellia Therapeutics to Present at March Healthcare Investor Conferences
February 28 2018 - 4:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of curative therapeutics using
CRISPR/Cas9 technology, will participate at the following upcoming
healthcare conferences in March:
Tuesday, March 13, 2018Barclays Capital
Global Healthcare ConferenceWho: John Leonard, M.D., Chief
Executive Officer and PresidentLocation: Miami, FloridaPresentation
Time: 3:50pm EST
Tuesday, March 20, 2018Morgan Stanley
Healthcare Corporate Access DayWho: Tom Barnes, Ph.D.,
Senior Vice President, Innovative SciencesLocation: Boston,
MassachusettsOne on one meetings only
Wednesday, March 21, 2018Oppenheimer
& Co. 28th Annual Healthcare ConferenceWho: Tom
Barnes, Ph.D., Senior Vice President, Innovative SciencesLocation:
New York, New YorkPresentation Time: 1:35pm EST
A live webcast of Intellia’s presentations will be accessible
through the Events and Presentations page of the Investor Relations
section of the company’s website at www.intelliatx.com. To access
the webcasts, please log on to the Intellia website approximately
15 minutes prior to the start time to ensure adequate time for any
software downloads that may be required. A replay of the webcast
will be available on Intellia’s website for 14 days following each
conference.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company focused on the
development of proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us
on Twitter @intelliatweets.
Investor
Contact:
Lindsey Trickett Vice President, Investor Relations +1
857-285-6211lindsey.trickett@intelliatx.com
Media Contact:Jennifer Mound Smoter Senior Vice
President, External Affairs & Communications +1 857-706-1071
jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024